Come and learn from two producers of significant alternatives to HBCD containing products, commercially available, how viable these solutions have been so far. The objective of this webinar is also to discuss the availability and effectiveness of these solutions, four years after the listing of HBCD in Annex A to the Stockholm Convention, in 2013.